

Alexa Fluor® 488 anti-mouse IL-10

| | |
|--------------------------|--|
| Catalog # / Size: | 3125065 / 100 µg |
| Clone: | JES5-16E3 |
| Isotype: | Rat IgG2b, κ |
| Immunogen: | <i>E. coli</i> -expressed, recombinant mouse IL-10 |
| Reactivity: | Mouse |
| Preparation: | The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 488 under optimal conditions. |
| Formulation: | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Concentration: | 0.5 |

Applications:

| | |
|---------------------------|--|
| Applications: | Flow Cytometry |
| Recommended Usage: | Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 microg per 10^6 cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm. |
| Application Notes: | ELISA or ELISPOT Detection^{1,9,11}: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. No. 504902/504904) as the capture antibody. Neutralization¹⁴: The LEAF™ purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10. Flow Cytometry³: The fluorochrome-labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations. Additional reported applications (for relevant formats) include: immunohistochemistry ³ . |

| | |
|--------------------------------|---|
| Application References: | <ol style="list-style-type: none">1. Simkin G, <i>et al.</i> 2000. <i>J. Immunol.</i> 164:2457.2. Kitagaki K, <i>et al.</i> 2002. <i>Clin. Diagn. Lab Immunol.</i> 9:1260.3. Khanna A, <i>et al.</i> 2000. <i>J. Immunol.</i> 164:1346.4. Sander B, <i>et al.</i> 1993. <i>J. Immunol. Methods</i> 166:201.5. Litton M, <i>et al.</i> 1994. <i>J. Immunol. Methods</i> 175:47.6. Andersson U, <i>et al.</i> 1999. <i>Detection and quantification of gene expression.</i> New York:Springer-Verlag.7. Finkelman F, <i>et al.</i> 2003. <i>Curr. Prot. Immunol.</i> John Wiley & Sons New York. Unit 6.28.8. Wang W, <i>et al.</i> 2004. <i>FASEB J.</i> 18:1043.9. Brummel R and Lenert P. 2005. <i>J. Immunol.</i> 174:2429. |
|--------------------------------|---|

10. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
 11. Xu G, *et al.* 2007. *J. Immunol.* 179:5358. [PubMed](#)
 12. Brummel R, *et al.* 2005. *J. Immunol.* 174:2429. [PubMed](#)
 13. Kang YJ, *et al.* 2007. *Stem Cells* 25:1814. [PubMed](#)
 14. Seo N, *et al.* 2001. *Immunology.* 103:449. (Neut)
-

Description: IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRF1. IL-10 inhibits IFN- γ , TNF- β , and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF- α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.

Antigen
References:

1. Fitzgerald K, *et al.* Eds. 2001. *The Cytokine FactsBook.* Academic Press San Diego.
2. de Waal-Malefy R, *et al.* 1992. *Curr. Opin. Immunol.* 4:314.
3. Howard M, *et al.* 1992. *Immunol. Today* 13:198.